APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

49 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-31

Study Completion Date

2010-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Reocclusion of the infarct artery is observed in about 30% of patients within three months after successful thrombolysis for acute myocardial infarction (MI). Reocclusion is associated with an increased risk of death, reinfarction and the need for revascularization. Even in the absence of clinical reinfarction, reocclusion results in impaired left ventricular (LV) recovery, leaving patients at increased risk of developing heart failure in the long-term. Prevention of reocclusion is therefore warranted. In previous trials, severity of the infarct related stenosis was the only independent predictor of reocclusion. With a lack of clinical predictors of reocclusion, many cardiologists therefore empirically favor routine revascularization after successful thrombolysis.

The APRICOT-3 will be the first randomized trial in the current era of improved angioplasty techniques to study the question of whether a routine invasive strategy after successful thrombolysis can reduce the incidence of reocclusion and subsequently improve clinical outcome and LV-function. After successful thrombolysis, patients will be randomized to either a routine invasive strategy or an ischemia-guided strategy. The investigators expect to demonstrate a lower reocclusion rate at the 6-month follow-up angiography (primary endpoint) and fewer associated events (death, reinfarction, revascularization, admissions for heart failure) in the routine invasive arm. In search of non-invasive parameters predictive of reocclusion, laboratory analysis of several coagulation and inflammatory markers will be performed. Finally, pooled analysis of all 3 APRICOT trials will focus on the identification of clinical predictors of reocclusion that can easily be obtained by history and physical examination.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase III Acute Coronary Syndrome

NCT00831441

Acute Coronary Syndrome

TERMINATED PHASE3

Thrombectomy and Improvement of Left Ventricular Function in AMI

NCT00288665

Acute Myocardial Infarction Ventricular Remodeling

COMPLETED PHASE4

Antegrade Dissection and Re-entry Versus Retrograde Strategy in CTO PCI

NCT06878729

Coronary Artery Disease Coronary Occlusion Percutaneous Coronary Intervention

RECRUITING NA

Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients

NCT00379418

Coronary Artery Disease

COMPLETED

CARESS in Acute Myocardial Infarction

NCT00220571

Myocardial Infarction

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Randomized controlled study of elective percutaneous coronary intervention (PCI) of an open culprit lesion after fibrinolysis for ST-elevation myocardial infarction (STEMI)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Percutaneous coronary intervention (PCI)

Stenting of the culprit lesion of the infarct related artery and aspirin and clopidorgel for at least 6 months

Group Type ACTIVE_COMPARATOR

Percutaneous coronary intervention (PCI)

Intervention Type PROCEDURE

PCI with bare metal stent placement of the culprit lesion the in the infarct related artery

Dual antiplatelet therapy

Aspirin and clopidogrel for at least 6 months

Group Type OTHER

Percutaneous coronary intervention (PCI)

Intervention Type PROCEDURE

PCI with bare metal stent placement of the culprit lesion the in the infarct related artery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Percutaneous coronary intervention (PCI)

PCI with bare metal stent placement of the culprit lesion the in the infarct related artery

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

bare metal stent placement

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* TIMI-3 in infarct-related artery with a stentable lesion with 72 hours of thrombolysis for ST-elevation myocardial infarction

Exclusion Criteria

* Use of oral anticoagulants.
* Known intolerance to aspirin or clopidogrel.
* Bypass graft as infarct-related artery.
* Previously dilated infarct related artery.
* Significant left main stenosis.
* Unidentifiable culprit stenosis.

Eligible Sex

ALL

Accepts Healthy Volunteers

No